Advertisement
Advertisement

OCUL

OCUL logo

Ocular Therapeutix Inc

8.34
USD
-0.225
-2.63%
Dec 24, 12:59 UTC -5
Closed
...

Ocular Therapeutix Inc Profile

About

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.

Info & Links

CEO

Antony Mattessich

Headquarters

15 CROSBY DRIVE
BEDFORD, MA 01730, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

29

Employees

267

Ocular Therapeutix Inc Statistics

Valuation Measures

Market Capitalization2

1.31B

Enterprise Value

951.02M

Enterprise Value/EBITDA(ttm)

-6.92

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

21.75

Price to Book(mrq)

3.76

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

90.59%

Operating Margin(ttm)

-225.91%

Profit Margin(ttm)

-284.80%

Return on Equity(ttm)

-45.18%

Return on Invested Capital(ttm)

-49.80%

Return on Assets(ttm)

-30.87%

Income Statement

Revenue(ttm)

61.44M

Revenue Per Share(ttm)

0.39

Gross Profit(ttm)

55.66M

EBITDA(ttm)3

-137.46M

Net Income Available to Common(ttm)

-174.34M

Diluted EPS(ttm)

-1.32

Share Statistics

Beta (5Y Monthly)

1.20

52-Week Change

148.07%

S&P 500 52-Week Change

26.50%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

157.22M

Dividend Yield

0.00%

Float4

151.71M

% Held by Insiders

3.50%

% Held by Institutions

59.21%

Balance Sheet

Total Cash(mrq)

427.22M

Total Cash Per Share(mrq)

2.72

Total Debt(mrq)

67.81M

Total Debt/Equity(mrq)

19.26%

Current Ratio(mrq)

13.01%

Quick Ratio(mrq)

12.94%

Book Value Per Share(mrq)

2.25

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.57

Free Cash Flow(ytd)

-96.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement